All the news

Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ...

Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ...

Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ...

Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate lower drug prices, a study presented online at this ...

Tenofovir alafenamide (TAF; Vemlidy) is highly effective at preventing transmission of hepatitis B virus (HBV) from mothers with a high viral load to their infants, according to a pair of studies presented ...

Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ...

NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen levels and several study participants achieved a functional cure after ...

Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ...

Decompensated cirrhosis, alcoholic liver disease and hepatocellular carcinoma each raise the risk of death and severe illness from COVID-19 among people with chronic liver disease, but other liver conditions do not, a US ...

Peers are important sources of information about hepatitis C treatment and may be the most persuasive advocates for engaging with treatment and care among drug users, a study in Melbourne, Australia, shows. People ...